Hypothesis

Age‑related loss of butyrate‑producing Firmicutes reduces colonic butyrate, which normally activates FFAR2 on colonocytes. We propose that sustained FFAR2 signaling maintains NAD+ biosynthesis by stimulating the NAMPT pathway via a cAMP‑PKA‑CREB axis. When butyrate falls, FFAR2 activity declines, leading to reduced NAMPT expression, lower NAD+ levels, and a downstream shift toward a low‑energy, protective state. This is not a passive downturn but an active, microbiome‑driven downgrading of cellular ambition.

Mechanistic Reasoning

1. Butyrate‑FFAR2 coupling – Butyrate is a potent agonist of FFAR2, raising intracellular cAMP and activating PKA. PKA phosphorylates CREB, which binds the promoter of Nampt, the rate‑limiting enzyme in the NAD+ salvage pathway (2).
2. NAD+‑dependent SIRT1 activity – Adequate NAD+ sustains SIRT1 deacetylation of PGC‑1α and FOXO3, promoting mitochondrial fatty‑acid oxidation and barrier‑protective gene expression (4).
3. Feedback loop – Falling NAD+ diminishes SIRT1 activity, increasing acetylation of HIF‑1α, which stabilizes HIF‑1α even under low oxygen. HIF‑1α drives expression of glycolytic genes and suppresses Nampt, further lowering NAD+—a bistable switch that locks colonocytes into a low‑metabolism state.
4. Pathological outcome – Low NAD+ compromises PARP1‑mediated DNA repair and tight‑junction protein acetylation, increasing permeability. Simultaneously, reduced butyrate‑FFAR2 signaling diminishes the hypoxic lumen gradient, allowing oxygen influx and expansion of aerobic Proteobacteria, amplifying inflammation.

Testable Predictions

• Prediction 1: Pharmacologic activation of FFAR2 (e.g., with the agonist 4‑CMTB) in aged mice will restore colonic NAD+ levels and Nampt expression despite an unchanged dysbiotic microbiota.
• Prediction 2: Colonocyte‑specific knockout of Ffar2 will reproduce the age‑associated NAD+ drop and barrier leak even in young, conventionally raised mice.
• Prediction 3: Supplementing butyrate alone will not rescue NAD+ if FFAR2 signaling is blocked, indicating that the receptor, not the metabolite per se, is essential.
• Prediction 4: Inhibiting SIRT1 (with EX‑527) will abolish the protective effect of FFAR2 activation on barrier integrity, placing SIRT1 downstream of the FFAR2‑NAD+ axis.

Experimental Approach

1. In vivo – Treat 20‑month‑old mice with FFAR2 agonist or vehicle for 4 weeks. Measure colonic NAD+ (LC‑MS), Nampt mRNA (qPCR), SIRT1 activity (acetyl‑p53 assay), mucin Muc2 (immunofluorescence), and FITC‑dextran permeability.
2. Ex vivo – Isolate colonic crypts from wild‑type and Ffar2−/− mice; expose to butyrate ± FFAR2 antagonist; assess NAD+ and Nampt.
3. Mechanistic – Use cAMP analogues and PKA inhibitors to dissect the signaling chain; perform ChIP for CREB binding at the Nampt promoter.
4. Microbiota transfer – Colonize germ‑free young mice with aged microbiota ± FFAR2 agonist; test whether NAD+ rescue occurs independent of microbiota composition.

Falsifiability

If FFAR2 activation fails to elevate colonic NAD+ or improve barrier function in aged mice, or if Ffar2 deletion does not recapitulate the NAD+ decline, the hypothesis would be refuted. Likewise, rescuing NAD+ with NR without FFAR2 activation should not restore barrier integrity if the pathway is strictly dependent on FFAR2‑SIRT1 signaling.

This framework shifts the narrative from passive NAD+ loss to an active, microbiome‑regulated metabolic downgrading, offering a precise intervention point: targeting the FFAR2‑NAD+‑SIRT1 axis to restore colonocyte energetics and mitigate inflammaging.